![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
#ClinicalTrial EAA173/DETER-SMM, led by @nsc_natalie of @UWCarbone, is a randomized phase 3 trial for patients with smoldering #MultipleMyeloma (#SMM) and high-risk features. Learn more here: https://bit.ly/eaa173detersmm #mmsm #BloodCancer
The MM1OA-EA02 clinical study is testing a new treatment approach for patients with #AcuteMyeloidLeukemia who are age 60 or older. Learn more: https://bit.ly/mm1oa-ea02-study #AML #leukemia
The EAF223/GABLE clinical study is testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: https://bit.ly/gable-trial
cc: @DukeRadiology, @glioblastf, @gbmfoundation
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
40
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
